Antisense oligonucleotide repress telomerase activity via manipulating alternative splicing or translation
- 21 October 2021
- journal article
- research article
- Published by Elsevier BV in Biochemical and Biophysical Research Communications
- Vol. 582, 118-124
- https://doi.org/10.1016/j.bbrc.2021.10.034
Abstract
No abstract availableKeywords
Funding Information
- Tianjin Research Program of Application Foundation and Advanced Technology of China (19JCZDJC35600)
- National Natural Science Foundation of China (19JCJQJC63500, 31471293, 31771520, 32170762, 81771135, 81772243, 81970958, 91649102)
This publication has 19 references indexed in Scilit:
- A Common Cancer Risk-Associated Allele in the hTERT Locus Encodes a Dominant Negative Inhibitor of TelomerasePLoS Genetics, 2015
- Phosphorothioates, Essential Components of Therapeutic OligonucleotidesNucleic Acid Therapeutics, 2014
- Tumor-targeted in vivo gene silencing via systemic delivery of cRGD-conjugated siRNANucleic Acids Research, 2014
- Scaffolding along Nucleic Acid Duplexes Using 2′-Amino-Locked Nucleic AcidsAccounts of Chemical Research, 2014
- Regulation of human telomerase splicing by RNA:RNA pairingNature Communications, 2014
- Regulation of Telomerase Alternative Splicing: A Target for ChemotherapyCell Reports, 2013
- Is telomerase a viable target in cancer?Mutation research. Reviews in mutation research, 2012
- A Direct Comparison of Anti-microRNA Oligonucleotide PotencyPharmaceutical Research, 2010
- Oligomer-mediated modulation of hTERT alternative splicing induces telomerase inhibition and cell growth decline in human prostate cancer cellsCellular and Molecular Life Sciences, 2004
- Stringent sequence requirements for the formation of human telomeres.Proceedings of the National Academy of Sciences of the United States of America, 1994